ImmunityBio
IBRX
165 hedge funds and large institutions have $357M invested in ImmunityBio in 2024 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 49 increasing their positions, 43 reducing their positions, and 16 closing their positions.
119% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 16
22% more capital invested
Capital invested by funds: $292M → $357M (+$65M)
14% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 43
12% more funds holding
Funds holding: 147 → 165 (+18)
1.15% more ownership
Funds ownership: 8.71% → 9.85% (+1.1%)
9% more call options, than puts
Call options by funds: $26.4M | Put options by funds: $24.4M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$21.3M |
| 2 |
PA
Perceptive Advisors
New York
|
+$4.77M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4M |
| 4 |
Citigroup
New York
|
+$3.7M |
| 5 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
+$3.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.6M |
| 2 |
Jane Street
New York
|
-$2.33M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.61M |
| 4 |
BlackRock
New York
|
-$1.52M |
| 5 |
NYLIM
New York Life Investment Management
New York
|
-$960K |
IBRX Hedge Fund Activity: Q1 2024 in Review
165 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2024, worth a combined $357M — up 22% from $292M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new IBRX positions and 16 closed out — a net gain of 19 holders — while 49 added to existing stakes and 43 trimmed.
The largest buyer was State Street, adding an estimated $21.3M. The largest seller was Morgan Stanley, cutting an estimated $2.6M.
- 165 institutional investors held ImmunityBio (IBRX) as of Q1 2024, up from 147 in Q4 2023.
- Funds reported $357M of ImmunityBio stock for Q1 2024, up 22% quarter-over-quarter.
- 35 funds opened new ImmunityBio positions in Q1 2024 and 16 closed out, a net change of +19 holders.
- The largest ImmunityBio buyer in Q1 2024 was State Street, an estimated $21.3M added.
- The largest ImmunityBio seller in Q1 2024 was Morgan Stanley, an estimated $2.6M sold.
Based on aggregated 13F filings for Q1 2024.